A5045601532- SARS-CoV-2 and COVID-19 Research
- Immunotherapy and Immune Responses
- Influenza Virus Research Studies
- Animal Virus Infections Studies
- Viral Infections and Vectors
- Mosquito-borne diseases and control
- Respiratory viral infections research
- Viral gastroenteritis research and epidemiology
- Virology and Viral Diseases
- Immune Response and Inflammation
- Malaria Research and Control
- COVID-19 Clinical Research Studies
- Viral Infections and Outbreaks Research
- Herpesvirus Infections and Treatments
- Virus-based gene therapy research
- SARS-CoV-2 detection and testing
- Vector-Borne Animal Diseases
- interferon and immune responses
- Monoclonal and Polyclonal Antibodies Research
- Bacterial Infections and Vaccines
The University of Queensland
2017-2023
Abstract The current COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We demonstrate that despite large size of viral RNA genome (~30 kb), infectious full-length cDNA readily assembled in vitro a circular polymerase extension reaction (CPER) methodology without need for technically demanding intermediate steps. Overlapping fragments are generated from and together with linker fragment containing CMV promoter into single reaction. Transfection...
Two antibodies against flaviviruses Flaviviruses are a group of RNA viruses that include the human pathogens dengue virus, Zika and West Nile virus. The envelope protein (E) on virus surface has been target vaccine development, but problems have arisen with E, leading to enhanced infection. Now, Modhiran et al. Biering describe two different bind flavivirus NS1 prevent it from disrupting epithelial cells, which is associated severe disease. Both cross-react multiple proteins. reduce viremia...
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been identified as the causative agent of coronavirus disease 2019 and is capable human-to-human transmission rapid global spread. The emergence spread SARS-CoV-2 encouraged establishment a rapid, sensitive, reliable viral detection quantification methodology. Here, we present an alternative assay, termed immuno-plaque assay (iPA), which utilizes combination plaque immunofluorescence techniques. We have extensively optimized...
Efforts to develop and deploy effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue at pace. Here, we describe rational antigen design through manufacturability vaccine efficacy of a prefusion-stabilised spike (S) protein, Sclamp, in combination with the licensed adjuvant MF59 'MF59C.1' (Seqirus, Parkville, Australia).A panel recombinant Sclamp proteins were produced Chinese hamster ovary screened vitro select lead candidate. The structure this was...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 160 million people and resulted in 3.3 deaths, despite the availability of multiple vaccines, world still faces many challenges with their rollout. Here, we use high-density microarray patch (HD-MAP) to deliver a SARS-CoV-2 spike subunit vaccine directly skin. We show that is thermostable on patches, delivery enhancing both cellular antibody immune responses. Elicited antibodies potently neutralize clinically...
Abstract In August 2022, a novel henipavirus (HNV) named Langya virus (LayV) was isolated from patients with severe pneumonic disease in China. This is closely related to Mòjiāng (MojV), and both are divergent the bat-borne HNV members, Nipah (NiV) Hendra (HeV) viruses. The spillover of LayV first instance zoonosis humans outside NiV HeV, highlighting continuing threat this genus poses human health. work, we determine prefusion structures MojV F proteins via cryogenic electron microscopy...
Highlights•The antibody 3E31 recognizes a cryptic epitope on the dengue virus E protein•3E31 blocks viral fusion and neutralizes all four serotypes•No enhancement at sub-neutralizing levels•The represents potential target for safe immunotherapeutic vaccine designSummaryUnderstanding molecular basis of neutralizing response to (DENV) is an essential component in design development effective vaccines immunotherapeutics. Here we present structure cross-reactive, antibody, 3E31, complex with...
Dengue virus is the most important arbovirus impacting global human health, with an estimated 390 million infections annually, and over half world's population at risk of infection. While significant efforts have been made to develop effective vaccines mitigate this threat, task has proven extremely challenging, new approaches continually being sought. The majority protective, neutralizing antibodies induced during infection are targeted by envelope (E) protein, making it ideal candidate for...
The COVID-19 pandemic response has shown how vaccine platform technologies can be used to rapidly and effectively counteract a novel emerging infectious disease. speed of development for mRNA vector-based vaccines outpaced those subunit vaccines, however, offer advantages in terms safety stability. Here we describe technology, the molecular clamp, application four viruses from divergent taxonomic families: Middle Eastern respiratory syndrome coronavirus (MERS-CoV), Ebola virus (EBOV), Lassa...
The ongoing coronavirus disease 2019 (COVID-19) pandemic continues to disrupt essential health services in 90 percent of countries today. spike (S) protein found on the surface causative agent, SARS-CoV-2 virus, has been prime target for current vaccine research since antibodies directed against S were neutralize virus. However, as new variants emerge, mutations within have given rise potential immune evasion response generated by generation vaccines. In this study, a modified, HexaPro...
Subunit vaccines exhibit favorable safety and immunogenicity profiles can be designed to mimic native antigen structures. However, pairing with an appropriate adjuvant is imperative in order elicit effective humoral cellular immune responses. In this study, we aimed determine optimal the prefusion form of influenza haemagglutinin (HA) or respiratory syncytial virus (RSV) fusion (F) subunit BALB/c mice inform future vaccine selection. We tested a panel adjuvants, including aluminum hydroxide...
Abstract SARS-CoV-2 has infected over 160 million people and resulted in more than 3.3 deaths, we still face many challenges the rollout of vaccines. Here, use high-density microarray patch to deliver a spike subunit vaccine directly skin. We show vaccine, dry-coated on is thermostable, delivery via HD-MAP induced greater cellular antibody immune responses, with serum able potently neutralize clinically relevant isolates including those from B.1.1.7 B.1.351 lineages. Finally, single dose...
Abstract Efforts to develop and deploy effective vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continue at pace with more than 30 candidate now in clinical evaluation. Here we describe the preclinical development of an adjuvanted, prefusion-stabilised Spike (S) protein “Sclamp” subunit vaccine, from rational antigen design through assessing manufacturability vaccine efficacy. In mice, elicits high levels neutralising antibodies epitopes both within outside...
Nipah virus (NiV) and respiratory syncytial (RSV) possess two surface glycoproteins involved in cellular attachment membrane fusion, both of which are potential targets for vaccines. The majority vaccine development is focused on the (G) protein NiV, immunodominant target. In contrast, fusion (F) RSV main target development. Despite this, neutralising epitopes have been described NiV F G, making them alternate design. Through rational design, we developed a strategy applicable to...
Abstract Influenza viruses cause a significant number of infections and deaths annually. In addition to seasonal infections, the risk an influenza virus pandemic emerging is extremely high owing large reservoir diverse found in animals co-circulation many subtypes which can reassort into novel strains. Development universal vaccine has proven challenging. absence such vaccine, rapid response technologies provide best potential counter outbreak. Here, we demonstrate that modular trimerization...
Background: We assessed the safety and immunogenicity of an MF59-adjuvanted subunit vaccine for COVID-19 based on recombinant SARS-CoV-2 spike glycoprotein stabilised in a prefusion conformation by novel molecular clamp (Sclamp).Methods: Phase 1, double-blind, placebo-controlled trial conducted Australia (July 2020–ongoing; ClinicalTrials.gov NCT04495933). Healthy adults (18-55 years) received two doses placebo, 5-μg, 15-μg, or 45-μg Sclamp, one dose Sclamp followed 28 days apart (n=120; 24...
Efforts to develop and deploy effective vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) continue at pace. Here we describe rational antigen design through manufacturability vaccine efficacy, of a prefusion-stabilised Spike (S) protein, Sclamp. This strategy uses an orthogonal stabilisation approach compared canonical vaccines, in combination with the licensed adjuvant MF59 (Seqirus). In mice, Sclamp elicits high levels neutralising antibodies, as well broadly...